Immunocore Holdings PLC Sponsored ADR
IMCR Healthcare Biotechnology
Immunocore Holdings PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $400.0 million, up 29.0% from fiscal 2024. In the quarter to June 2026, revenue grew 18.3%, EPS grew 92.1%, free cash flow fell 40.7% and total debt was flat, each against the same quarter a year earlier. Revenue growth for three consecutive years.
Follow IMCR
Immunocore Holdings PLC Sponsored ADR (IMCR) P/E ratio
Immunocore Holdings PLC Sponsored ADR has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 20 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| QURE uniQure N.V. compare | n/m |
| ABSI Absci Corporation compare | n/m |
| RARE Ultragenyx Pharmaceutical Inc. compare | n/m |
| MAZE Maze Therapeutics, Inc. compare | n/m |
| NTLA Intellia Therapeutics, Inc. compare | n/m |
| KRSA Korsana Biosciences, Inc. compare | n/m |
| IMCR Immunocore Holdings PLC Sponsored ADR | n/m |
| GPCR Structure Therapeutics Inc. Sponsored ADR compare | n/m |
| ANAB AnaptysBio, Inc. compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)